BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. ...Middle East

– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid...

Hence then, the article about biolinerx and ayrmid ltd enter into exclusive license agreement to commercialize aphexda motixafortide through gamida cell ltd was published today ( Thursday 21/11/2024 - 02:36 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. )

Also on site :

• Best-Selling Author’s Novel, Ranked ‘Readers’ Favorite Mystery and Thriller,’ Was Built on a Wild Premise
• Meta’s AI Is Delivering but Comes With a Hefty Price Tag .. PYMNTS.com
• Meta looks to report fastest revenue growth since 2021